| US 7,517,902 B2 | ||
| Substituted indazoles, compositions containing the same, and the preparation and use thereof | ||
| Frank Halley, Chaville (France); Michel Tabart, La Norville (France); Hervé Bouchard, Thiais (France); Catherine Souaille, Choisy le Roi (France); Alain Le Brun, Vigneux (France); Fabrice Viviani, Louvres (France); Laurence Gauzy-Lazo, Paris (France); Pascal Desmazeau, Tigery (France); Odile Angouillant-Boniface, Paris (France); and Bruno Filoche-Romme, Creteil (France) | ||
| Assigned to Aventis Pharma S.A., Antony (France) | ||
| Filed on Dec. 04, 2006, as Appl. No. 11/566,382. | ||
| Application 11/566382 is a continuation of application No. PCT/FR2005/001335, filed on Jun. 01, 2005. | ||
| Claims priority of application No. 04 06042 (FR), filed on Jun. 04, 2004. | ||
| Prior Publication US 2007/0161626 A1, Jul. 12, 2007 | ||
| Int. Cl. A61K 31/541 (2006.01); A61K 31/5377 (2006.01); C07D 417/02 (2006.01); C07D 413/02 (2006.01) | ||
| U.S. Cl. 514—406 [514/227.8; 514/234.2; 514/254.06; 514/256; 544/60; 544/140; 544/333; 544/371; 546/275.7; 548/206; 548/215; 548/247; 548/312.1; 548/360.1] | 23 Claims |
1. A compound according to formula (I):
 A is selected from the group consisting of: H, aryl, heteroaryl, substituted aryl, and substituted heteroaryl;
Ar is selected from the group consisting of: aryl, heteroaryl, substituted aryl, and substituted heteroaryl;
L is selected from the group consisting of: NH—SO2, SO2NH, and NH—CO—NH;
M is selected from the group consisting of: a bond, CO, NH, CO—NH, CS—NH, NH—CO, NH—SO, NH—SO2, CO—NH—SO2, NH—CH2, CH2—CO—NH, NH—CO—CH2, NH—CH2—CO, and CO—CH2—NH;
R3 is independently selected from the group consisting of H, alkyl, alkylene, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl,
substituted alkyl, substituted alkylene, substituted alkynyl, substituted aryl, substituted heteroaryl, substituted cycloalkyl,
substituted heterocyclyl, alkylene, substituted alkylene, and substituted alkynyl;
R4 and R5 are independently selected from the group consisting of: H, halogen, R2, CN, O(R2), OC(O)(R2), OC(O)N(R2)(R1), OS(O2)(R2), N(R2)(R1), N═C(R2)(R1), N(R2)C(O)(R1), N(R2)C(O)O(R1), N(R6)C(O)N(R2)(R1), N(R6)C(S)N(R2)(R1), N(R2)S(O2)(R1), C(O)(R2), C(O)O(R2), C(O)N(R2)(R1), C(═N(R1))(R2), C(═N(OR1))(R2), S(R2), S(O)(R2), S(O2)(R2), S(O2)O(R2), and S(O2)N(R2)(R1); wherein each R2, R1, R6 is independently selected from the group consisting of H, alkyl, alkylene, alkynyl, aryl,
heteroaryl, cycloalkyl, heterocyclyl, substituted alkyl, substituted alkylene, substituted alkynyl, substituted aryl, substituted
heteroaryl, substituted cycloalkyl, substituted heterocyclyl, alkylene, substituted alkylene, and substituted alkynyl; wherein,
when R2 and R1 are simultaneously present on one of R4 and R5, they may be linked to one another to form a ring;
R7 is fluoro; or a pharmaceutically acceptable salt thereof.
|